FDA moves to waive immunogenicity studies for biosimilar insulin

FDA issued draft guidance on Tuesday that would streamline the approval process for certain biosimilar or interchangeable insulin products by eliminating the need for costly and time-consuming comparative clinical immunogenicity

Read the full 307 word article

User Sign In